On Jan. 4, 2021, Inovio Pharmaceuticals and Advaccine Biopharmaceuticals announced that they had entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan.